Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS
F. Shawket,
J. Lycke,
J. Salzer,
F. Piehl,
K. Fink,
N. Lange,
J. Mellergård,
C. Malmeström,
P. Sundström,
I. Erngren,
A. al‐Grety,
E. Freyhult,
K. Kultima,
J. Burman,
A. Svenningsson Annals of Clinical and Translational Neurology
· Wiley
· 2026-11-12
· DOI: 10.1002/acn3.70395
The publisher did not provide an abstract — full text is available via the link below.
F. Shawket, J. Lycke, J. Salzer, F. Piehl, K. Fink, N. Lange et al. Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS. // Annals of Clinical and Translational Neurology. – 2026. – DOI: 10.1002/acn3.70395. – URL: https://onlinelibrary.wiley.com/doi/10.1002/acn3.70395?af=R
F. Shawket, J. Lycke, J. Salzer, F. Piehl, K. Fink, N. Lange, J. Mellergård, C. Malmeström, P. Sundström, I. Erngren, A. al‐Grety, E. Freyhult, K. Kultima, J. Burman, & A. Svenningsson (2026). Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70395
F. Shawket, et al. “Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS.” Annals of Clinical and Translational Neurology, 2026. doi:10.1002/acn3.70395.
@article{Shawket2026,
title = {Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS},
author = {Shawket, F. and Lycke, J. and Salzer, J. and Piehl, F. and Fink, K. and Lange, N. and Mellergård, J. and Malmeström, C. and Sundström, P. and Erngren, I. and al‐Grety, A. and Freyhult, E. and Kultima, K. and Burman, J. and Svenningsson, A.},
journal = {Annals of Clinical and Translational Neurology},
year = {2026},
doi = {10.1002/acn3.70395},
url = {https://onlinelibrary.wiley.com/doi/10.1002/acn3.70395?af=R}
}